These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 3964880

  • 1. Treatment of prostatic cancer: effects on serum lipoproteins and the cardiovascular system.
    Rössner S, Hedlund PO, Jogestrand T, Säwe U.
    J Urol; 1985 Jan; 133(1):53-7. PubMed ID: 3964880
    [Abstract] [Full Text] [Related]

  • 2. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma.
    Agardh CD, Nilsson-Ehle P, Lundgren R, Gustafson A.
    J Urol; 1984 Nov; 132(5):1021-4. PubMed ID: 6492270
    [Abstract] [Full Text] [Related]

  • 3. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R, Nordle O, Josefsson K.
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [Abstract] [Full Text] [Related]

  • 4. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
    Aro J, Haapiainen R, Sane T, Rannikko S, Pelkonen R, Alfthan O.
    Eur Urol; 1990 May; 17(3):229-35. PubMed ID: 2351192
    [Abstract] [Full Text] [Related]

  • 5. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.
    Damber JE, Daehlin L, Tomic R, Nilsson TK.
    Int Urol Nephrol; 1991 May; 23(3):251-6. PubMed ID: 1889971
    [Abstract] [Full Text] [Related]

  • 6. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
    Wallentin L, Varenhorst E.
    J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J.
    Prostate; 1991 Dec; 18(2):131-7. PubMed ID: 2006119
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R, Sundin T, Colleen S, Lindstedt E, Wadström L, Carlsson S, Hellsten S, Pompeius R, Holmquist B, Nilsson T.
    Scand J Urol Nephrol; 1986 Dec; 20(2):101-5. PubMed ID: 3529368
    [Abstract] [Full Text] [Related]

  • 9. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E.
    Scand J Urol Nephrol Suppl; 1980 Dec; 55():95-7. PubMed ID: 6938044
    [Abstract] [Full Text] [Related]

  • 10. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
    Carlström K, Stege R.
    Urol Int; 1990 Dec; 45(3):160-3. PubMed ID: 2161578
    [Abstract] [Full Text] [Related]

  • 11. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L, Damber JE, von Schoultz B, Bergman B.
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [Abstract] [Full Text] [Related]

  • 12. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.
    Henriksson P, Johansson SE.
    Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255
    [Abstract] [Full Text] [Related]

  • 13. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R, Rannikko S, Alfthan O, Adlercreutz H.
    Scand J Urol Nephrol Suppl; 1988 Jun; 110():137-43. PubMed ID: 3187401
    [Abstract] [Full Text] [Related]

  • 14. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J, Haapiainen R, Kajanti M, Rannikko S, Alfthan O.
    Scand J Urol Nephrol Suppl; 1988 Jun; 110():103-7. PubMed ID: 3187397
    [Abstract] [Full Text] [Related]

  • 15. Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.
    Henriksson P, Edhag O, Eriksson A, Johansson SE.
    Br J Urol; 1989 Feb; 63(2):186-90. PubMed ID: 2649197
    [Abstract] [Full Text] [Related]

  • 16. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R, Rannikko S, Alfthan O.
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [Abstract] [Full Text] [Related]

  • 17. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA.
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [Abstract] [Full Text] [Related]

  • 18. Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
    Aro J, Haapiainen R, Kajanti M, Rannikko S, Alfthan O.
    Eur Urol; 1988 Aug; 15(3-4):182-6. PubMed ID: 3063541
    [Abstract] [Full Text] [Related]

  • 19. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
    Tomić R.
    Scand J Urol Nephrol Suppl; 1983 Aug; 77():1-37. PubMed ID: 6426040
    [Abstract] [Full Text] [Related]

  • 20. Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer.
    Henriksson P, Linde B, Edhag O.
    Eur Heart J; 1987 Jul; 8(7):779-84. PubMed ID: 3653128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.